COMMUNIQUÉS West-GlobeNewswire

-
HNL Lab Medicine Begins Subtyping Positive Flu A Samples for H5N1 Avian Influenza
20/02/2025 -
Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology
20/02/2025 -
NanoNewron and its Research to Advance the Treatment of Alzheimer’s Disease are Featured by Rutgers University Newsletters and on Rutgers Today
20/02/2025 -
OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO
20/02/2025 -
OSE Immunotherapeutics présente des données précliniques positives sur l'anti-IL-7 récepteur Lusvertikimab en combinaison dans la colite chronique En présentation orale au 20ème congrès de l’ECCO
20/02/2025 -
Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy
20/02/2025 -
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)
20/02/2025 -
Egetis Therapeutics to Feature MCT8 Deficiency on Behind the Mystery Airing on Lifetime in Honor of Rare Disease Day
20/02/2025 -
Acentra Health Employees Provide Over 3,000 Hours of Volunteer Work to Promote Healthier Communities
20/02/2025 -
60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split
20/02/2025 -
Serenity Medical Announces Clinical Publication of First Prospective Multicenter Trial of the River™ Stent, a Novel Venous Sinus Stent for Treating Idiopathic Intracranial Hypertension (IIH)
20/02/2025 -
Anbio Biotechnology Announces Closing of Initial Public Offering
20/02/2025 -
Intelligent Bio Solutions Inc. Announces Proposed Public Offering of Common Stock
19/02/2025 -
Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference
19/02/2025 -
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19/02/2025 -
ANI Pharmaceuticals to Present at Raymond James’ Institutional Investors and Leerink Partners Global Healthcare Conferences in March
19/02/2025 -
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025
19/02/2025 -
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025
19/02/2025 -
PacBio to Participate in TD Cowen's 45th Annual Health Care Conference
19/02/2025
Pages